Supplementary Table 1.

Prognosis of IBD patients with EB-DNA positive in blood: patients with antiviral therapy and patients without antiviral therapy

	Antiviral therapy (n=17)	Non-antiviral therapy (n=31)	P
Post - admission treatment, n (%)
GS	10 (58.8%)	16 (51.6%)	0.632
AZA/6-MP	5 (29.4%)	11 (35.4%)	0.670
IFX	2 (11.8%)	2 (6.5%)	0.524
IFX+AZA	0	2 (6.5%)	0.285
EBV-DNA was negative in duplicates after 2 weeks	14 (82.4%)	26 (83.9%)	0.893
EBV-DNA was negative in duplicates after 4 weeks	17 (100.0%)	31 (100.0%)	-
Clinical remission within 3 months
UC n (n) (%)	8 (12) (66.7%)	12 (16) (75.0%)	0.629
CD n (n) (%)	3 (5) (60.0%)	10 (15) (66.7%)	0.787
Surgery within 3 months, n (%)	4 (23.6%)	5 (16.1%)	0.530
Lymphoma was observed during the follow-up, n (%)	1 (5.9%)	0 (0.0%)	0.172
CAEBV was observed during the follow-up, n (%)	0 (0.0%)	0 (0.0%)	-

IBD, Inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; CAEBV: chronic activity Epstein-Barr virus; EBV, Epstein-Barr virus; EBER-1, Epstein-Barr virus-encoded small-RNA 1; 5-ASA, 5-aminosalicylates; CS, corticosteroids; AZA, azathioprine; IFX, infliximab; IFX + AZA, infliximab in combination with azathioprine, all patients